Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Warrants and Derivative Liabilities (Details 1)

Warrants and Derivative Liabilities (Details 1) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Feb. 28, 2018	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		$ 558,037			$ 558,037	$ 1,231,129
Fair Value of Derivative Liabilities Issued	$ 5,707,423	4,717,211			10,424,634
Change in fair value of warrant liabilities			$ 1,050,729	$ (281,497)	1,468,477	(320,495)
Reclassification of Derivatives to Equity					(1,340,581)	(5,861)
Fair Value of Derivative Liabilities			11,110,567	816,241	11,110,567	816,241
Series B Warrant Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		551,322			551,322	1,112,308
Fair Value of Derivative Liabilities Issued					0	0
Change in fair value of warrant liabilities					1,275,669	(320,495)
Reclassification of Derivatives to Equity					(1,333,866)	0
Fair Value of Derivative Liabilities			493,125	791,813	493,125	791,813
Series B Preferred Stock Conversion Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		6,715			6,715	118,821
Fair Value of Derivative Liabilities Issued					0	0
Change in fair value of warrant liabilities					0	(88,532)
Reclassification of Derivatives to Equity					(6,715)	(5,861)
Fair Value of Derivative Liabilities			0	$ 24,428	0	$ 24,428
Emerald Financing - Warrant Liability
Fair Value Of Derivative Liabilities [Roll Forward]
Fair Value of Derivative Liabilities		$ 0			0
Fair Value of Derivative Liabilities Issued					10,424,634
Change in fair value of warrant liabilities					192,808
Reclassification of Derivatives to Equity					0
Fair Value of Derivative Liabilities			$ 10,617,442		$ 10,617,442